Nuscale Power earnings missed by $0.02, revenue fell short of estimates
In a recent filing with the Securities and Exchange Commission, Exelixis, Inc. (NASDAQ:EXEL) disclosed that Mary C. Beckerle, a director at the company, sold shares of the company’s common stock valued at approximately $425,878. The transactions took place on February 14, 2025. The stock has shown remarkable strength, delivering a 70% return over the past year and trading near its 52-week high of $37.59.
Beckerle sold a total of 12,210 shares at prices ranging from $34.87 to $34.90 per share. Following these transactions, Beckerle holds 30,406 shares of Exelixis common stock.
Additionally, Beckerle acquired 8,354 shares through the exercise of stock options at a price of $23.24 per share, which were part of a previously granted option that became fully exercisable in January 2024. This transaction was valued at $194,146.
These transactions are part of routine financial activities by executives and board members, reflecting ongoing management of personal portfolios. The company’s strong financial position is evident in its healthy balance sheet, with more cash than debt and a robust current ratio of 3.63. Exelixis, headquartered in Alameda, California, is a biotechnology company focused on developing treatments for cancer, currently valued at approximately $9.8 billion.
In other recent news, Exelixis has been the focus of several analyst updates and developments. JMP Securities maintained a Market Outperform rating with a $41 price target, noting that Exelixis’ fourth quarter 2024 revenue met market expectations. The firm highlighted the company’s focus on the investigational drug zanzalintinib, which is seen as a potential $5 billion opportunity. Meanwhile, Truist Securities raised its price target for Exelixis to $43, citing optimism from Phase 1 study results of zanzalintinib, which could lead to positive outcomes in the ongoing Phase 3 study.
Stifel analysts adjusted their price target for Exelixis to $36, maintaining a Hold rating. They noted the potential impact of Exelixis’s share repurchase program and the updated probability of success estimates for zanzalintinib in treating certain cancers. Despite these updates, the analysts remain cautious about the stock’s market performance. Additionally, Exelixis presented new data from the STELLAR-001 study at a recent meeting, which did not change Stifel’s outlook on the Phase 3 STELLAR-303 trial.
These recent developments reflect a mix of cautious optimism and strategic focus on Exelixis’s drug pipeline and financial maneuvers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.